Lv4
670 积分 2020-05-07 加入
A palmitoylation–depalmitoylation relay spatiotemporally controls GSDMD activation in pyroptosis
3天前
已完结
Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG
3天前
已完结
PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia
10天前
已完结
Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy
11天前
已完结
Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene
11天前
已完结
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
11天前
已完结
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
11天前
已完结
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
11天前
已关闭
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
11天前
已完结
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
11天前
已完结
皖公网安备34019202002308
